PIRPath: A region-guided weakly supervised pathomics framework for neoadjuvant immunotherapy response prediction across multiple cancer types

Background Neoadjuvant immunotherapy is now standard for multiple solid tumors; however, substantial heterogeneity in treatment response remains. Current biomarkers such as programmed death-ligand 1 (PD-L1) capture only limited molecular dimensions of tumor biology. We aimed to predict pathological response from pretreatment hematoxylin and eosin (H&E) whole-slide images (WSIs), benchmark it against PD-L1, and test cross-cancer transferability. Methods Across 320 patients, 377 pretreatment H&E WSIs were processed, yielding 20,247,535 tissue patches. We developed PIRPath (Pathomics for Immunotherapy Response Prediction), a region-guided weakly supervised framework, internally validated in a breast cancer cohort using five-fold cross-validation and further evaluated in two independent external cohorts. Exploratory cross-cancer transfer was assessed in lung cancer and esophageal squamous cell carcinoma cohorts. Results In breast cancer, PIRPath-BC achieved an AUC of 0.9318 (95% CI, 0.8836–0.9713) in internal validation and external AUCs of 0.7991 (95% CI, 0.6000–0.9509) and 0.7292 (95% CI, 0.5333–0.8947). High-score patients showed significantly higher pathological complete response (pCR) rates than low-score patients in both cohorts (78.6%vs 31.2%, P = 0.010; 70.6% vs 35.3%, P = 0.039). In cross-cancer transfer, PIRPath reached 0.7107 for major pathological response (MPR) and 0.7037 for pCR, versus 0.6125 and 0.4590 for PD-L1. Incremental analyses demonstrated additional predictive value beyond PD-L1. Exploratory transcriptomic analyses linked predictions to reduced stromal features and immune activation-related states. Conclusions H&E WSIs contain response-associated histological information not fully captured by conventional biomarkers. PIRPath provides a computational pathology framework for extracting this and complementing existing biomarkers in neoadjuvant immunotherapy stratification, although the modest external cohorts require prospective validation.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-21
DOI
https://doi.org/10.1016/j.tranon.2026.103127
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PIRPath: A region-guided weakly supervised pathomics framework for neoadjuvant immunotherapy response prediction across multiple cancer types

Peng Yuan, Jian Yue, Anjie Zhu, Jinyang Liu et al.
2 links
Translational Oncology
AI in cancer detection
article

PIRPath: A region-guided weakly supervised pathomics framework for neoadjuvant immunotherapy response prediction across multiple cancer types

Peng Yuan, Jian Yue, Anjie Zhu, Jinyang Liu, Zhao Bi, Jialiang Yang, Shufang Shi, Anqing Liu, Wenyu Yang
article en

Abstract

Background Neoadjuvant immunotherapy is now standard for multiple solid tumors; however, substantial heterogeneity in treatment response remains. Current biomarkers such as programmed death-ligand 1 (PD-L1) capture only limited molecular dimensions of tumor biology. We aimed to predict pathological response from pretreatment hematoxylin and eosin (H&E) whole-slide images (WSIs), benchmark it against PD-L1, and test cross-cancer transferability. Methods Across 320 patients, 377 pretreatment H&E WSIs were processed, yielding 20,247,535 tissue patches. We developed PIRPath (Pathomics for Immunotherapy Response Prediction), a region-guided weakly supervised framework, internally validated in a breast cancer cohort using five-fold cross-validation and further evaluated in two independent external cohorts. Exploratory cross-cancer transfer was assessed in lung cancer and esophageal squamous cell carcinoma cohorts. Results In breast cancer, PIRPath-BC achieved an AUC of 0.9318 (95% CI, 0.8836–0.9713) in internal validation and external AUCs of 0.7991 (95% CI, 0.6000–0.9509) and 0.7292 (95% CI, 0.5333–0.8947). High-score patients showed significantly higher pathological complete response (pCR) rates than low-score patients in both cohorts (78.6%vs 31.2%, P = 0.010; 70.6% vs 35.3%, P = 0.039). In cross-cancer transfer, PIRPath reached 0.7107 for major pathological response (MPR) and 0.7037 for pCR, versus 0.6125 and 0.4590 for PD-L1. Incremental analyses demonstrated additional predictive value beyond PD-L1. Exploratory transcriptomic analyses linked predictions to reduced stromal features and immune activation-related states. Conclusions H&E WSIs contain response-associated histological information not fully captured by conventional biomarkers. PIRPath provides a computational pathology framework for extracting this and complementing existing biomarkers in neoadjuvant immunotherapy stratification, although the modest external cohorts require prospective validation.

Translational OncologyVol. 75
Changsha Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Cancer Center (US), Shandong Tumor Hospital (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Ministry of Education (ET), Shandong First Medical University (CN)
Good health and well-being
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon